Clinical laboratories have spent the past several years navigating uncertainty surrounding the Protecting Access to Medicare Act (PAMA). Since Medicare first transitioned to market-based laboratory reimbursement, Congress has repeatedly delayed scheduled payment reductions, creating confusion about reporting requirements, reimbursement rates, and future financial planning.

In 2026, the conversation has shifted once again.

While Medicare reimbursement rates under the Clinical Laboratory Fee Schedule (CLFS) remain unchanged throughout 2026, applicable laboratories are now responsible for reporting updated private payer data that CMS will use to establish reimbursement rates beginning January 1, 2027. 

This reporting cycle is one of the most important since PAMA was enacted. The accuracy of the data submitted during 2026 will influence future Medicare reimbursement for thousands of Clinical Diagnostic Laboratory Tests (CDLTs). Laboratories that fail to prepare could face compliance issues, inaccurate reimbursement calculations, and long-term financial consequences.

Whether you operate an independent clinical laboratory, a hospital outreach laboratory, a physician office laboratory, or a specialty molecular or pathology lab, understanding the latest PAMA updates is essential for protecting revenue and maintaining compliance.

In this guide, you’ll learn:

• What changed under PAMA for 2026
• Which laboratories must report private payer data
• The latest reporting deadlines and requirements
• How CMS calculates reimbursement rates
• Which laboratory services could be most affected
• Practical strategies to prepare your laboratory for 2027 and beyond

PAMA 2026 at a Glance

Topic	2026 Update
Current reimbursement rates	No CLFS payment reductions during 2026
Data collection period	January 1, 2025 – June 30, 2025
Reporting window	May 1 – July 31, 2026
Data reported	Private payer rates, HCPCS codes, and test volumes
New Medicare reimbursement rates	Effective January 1, 2027
Maximum annual reduction (2027–2029)	15% per year
Governing program	Clinical Laboratory Fee Schedule (CLFS)

The updated reporting schedule was established under Section 6226 of the Consolidated Appropriations Act (CAA), 2026, which delayed CLFS payment reductions for another year while moving forward with a new private payer reporting cycle. 

What Is PAMA?

The Protecting Access to Medicare Act (PAMA) was signed into law in 2014 to modernize how Medicare pays for clinical laboratory testing.

Before PAMA, Medicare reimbursement under the Clinical Laboratory Fee Schedule relied on historical payment amounts that had changed very little over time. Lawmakers believed those rates no longer reflected the commercial insurance market.

PAMA replaced the old methodology with a market-based reimbursement model.

Instead of setting laboratory payment rates internally, CMS now calculates Medicare reimbursement using the weighted median of private payer rates reported by applicable laboratories. 

Under this system, laboratories periodically submit:

• Private payer reimbursement amounts
• HCPCS codes for each laboratory test
• Associated testing volumes

CMS analyzes this information and publishes updated reimbursement rates under the Clinical Laboratory Fee Schedule.

The overall objectives of PAMA include:

• Align Medicare reimbursement with the commercial insurance market
• Improve pricing transparency
• Reduce excessive Medicare spending
• Create a standardized reimbursement methodology for clinical diagnostic laboratory tests

Although the legislation has remained in effect since 2014, Congress has repeatedly postponed scheduled reimbursement reductions to reduce financial pressure on laboratories, particularly following the COVID-19 pandemic and continued concerns about access to laboratory services. 

PAMA Timeline: Understanding How We Got Here

One reason PAMA creates confusion is that Congress has revised the implementation schedule several times.

The following timeline summarizes the major milestones.

Year	Major Milestone
2014	PAMA becomes law and changes Medicare laboratory reimbursement methodology.
2017	First private payer reporting cycle begins.
2018	CMS implements the first CLFS rates based on reported private payer data.
2019–2025	Congress repeatedly delays scheduled reimbursement reductions through multiple legislative extensions.
2026	Laboratories report private payer data collected between January 1 and June 30, 2025. No CLFS payment reductions apply during 2026.
2027	CMS implements new reimbursement rates based on the 2026 reporting cycle. Payment reductions may be limited to 15% annually through 2029.

Understanding this timeline explains why many older articles reference different reporting years or deadlines. Several legislative updates have changed both the reporting schedule and the timing of reimbursement adjustments. 

Why PAMA Matters More in 2026 Than Many Laboratories Realize

At first glance, 2026 appears to be a relatively quiet year for Medicare laboratory reimbursement.

There are no scheduled CLFS payment reductions.

Existing reimbursement rates remain in place throughout the year.

For many laboratory administrators, that sounds like good news.

However, focusing only on today’s reimbursement rates misses the bigger picture.

The most important activity in 2026 is private payer data reporting.

Applicable laboratories must submit reimbursement information collected from January 1 through June 30, 2025, during the official reporting window of May 1 through July 31, 2026. CMS will use this data to calculate the next set of Medicare reimbursement rates that become effective on January 1, 2027. 

That means every reported payment amount and every reported testing volume has long-term financial implications.

For laboratory executives, the focus in 2026 should not simply be maintaining current reimbursement. It should be ensuring that reported data accurately reflects the laboratory’s private payer payments and testing activity.

Organizations that treat PAMA reporting as a routine administrative task risk introducing errors that may affect Medicare reimbursement for years to come.

Another reason 2026 is significant is that CMS has expanded its reporting resources to help laboratories prepare. Updated guidance now includes revised FAQs, reporting templates, HCPCS code lists, and Submitter and Certifier user guides, reinforcing CMS’s expectation that reporting entities validate their data before submission.

Finally, while reimbursement reductions are paused in 2026, the current law allows payment reductions of up to 15% per year beginning in 2027 if newly calculated CLFS rates are lower than existing rates. Laboratories that prepare now will be in a much stronger position to manage any future reimbursement changes. 

Major PAMA Changes for 2026

The most significant PAMA updates for 2026 are not centered on immediate Medicare payment reductions. Instead, they focus on updated reporting requirements that will shape future reimbursement under the Clinical Laboratory Fee Schedule (CLFS).

For laboratory owners and revenue cycle leaders, understanding these changes is essential for maintaining compliance and preparing for 2027 reimbursement rates.

1- No Medicare Payment Cuts During 2026

One of the biggest developments for clinical laboratories is that no CLFS payment reductions apply during calendar year 2026.

The Consolidated Appropriations Act (CAA), 2026 delayed the next round of scheduled PAMA reimbursement reductions by one year. As a result, Medicare continues to pay laboratories using the existing Clinical Laboratory Fee Schedule throughout 2026. 

This temporary relief provides laboratories with greater financial stability at a time when many organizations continue to face rising operating costs, workforce shortages, and increasing payer scrutiny.

Without this legislative action, many laboratory tests could have been subject to reimbursement reductions beginning in 2026.

Instead, laboratories have an additional year to strengthen operations before new payment rates take effect.

Although this delay is welcome news, it should not be viewed as a permanent solution. Congress has postponed PAMA payment reductions multiple times over the past several years, but the reporting requirements remain active.

2- New Private Payer Reporting Timeline

While reimbursement rates remain unchanged in 2026, the PAMA reporting cycle moves forward.

CMS requires applicable laboratories to report private payer reimbursement information collected during the first half of 2025.

Data Collection Period

January 1, 2025 – June 30, 2025

Reporting Window

May 1, 2026 – July 31, 2026 

During this reporting period, laboratories must submit:

• The HCPCS code for each Clinical Diagnostic Laboratory Test (CDLT)
• The final private payer reimbursement amount
• The corresponding test volume for each reported payment rate 

CMS emphasizes that the reported information must be based on final paid claims, not billed charges or estimated reimbursement amounts.

Because this information directly determines future Medicare reimbursement, laboratories should carefully validate every data element before submission.

3- New Medicare Reimbursement Rates Begin in 2027

Many laboratory administrators mistakenly believe that because reimbursement reductions are delayed in 2026, no further action is necessary.

In reality, 2026 is the foundation for 2027 reimbursement.

Once the reporting window closes, CMS will analyze the submitted private payer data and calculate updated reimbursement rates using the weighted median methodology.

Those revised payment amounts become effective on January 1, 2027. 

Current legislation also limits reimbursement reductions to no more than 15% per year between 2027 and 2029, providing a phased approach rather than immediate large-scale reductions. 

Laboratories therefore have a limited opportunity to improve reporting accuracy before these new rates are established.

Which Laboratory Tests Could Be Most Affected?

PAMA does not apply a single reimbursement adjustment across every laboratory service.

Instead, CMS calculates reimbursement individually for each HCPCS code using reported private payer payment data.

Although the exact payment changes will not be known until CMS completes its calculations, laboratories that perform large volumes of routine Medicare testing should pay close attention to future reimbursement trends.

Services commonly monitored include:

• Complete Blood Count (CBC)
• Basic Metabolic Panel (BMP)
• Comprehensive Metabolic Panel (CMP)
• Lipid Panel
• Hemoglobin A1c
• Thyroid Function Tests
• Urinalysis
• Microbiology Testing
• Molecular Diagnostic Testing
• Toxicology Testing
• Infectious Disease Testing
• Pathology and Histology Services
• Genetic Testing

For laboratories that rely heavily on Medicare revenue, even relatively small reimbursement adjustments across high-volume tests can significantly affect annual collections.

Specialty laboratories performing molecular diagnostics, pathology, toxicology, and genetic testing should also monitor future CLFS updates because reimbursement changes vary by individual HCPCS code rather than laboratory specialty. 

Which Laboratories Must Report Under PAMA?

Not every laboratory participating in Medicare is required to submit private payer information.

PAMA reporting applies only to organizations that meet CMS’s definition of an applicable laboratory.

Generally, reporting entities include:

• Independent clinical laboratories
• Physician office laboratories
• Hospital outreach laboratories that bill Medicare Part B under the appropriate requirements

In addition, laboratories must satisfy CMS’s applicable laboratory criteria, including the Medicare revenue threshold and other reporting requirements established by the agency.

Reporting is completed at the Tax Identification Number (TIN) level rather than by each individual laboratory location.

The reporting entity is responsible for collecting and submitting data from all applicable component laboratories operating under that TIN.

Which Laboratories Are Not Required to Report?

A common misconception is that every clinical laboratory must participate in PAMA reporting.

In reality, many organizations do not qualify as applicable laboratories.

Depending on CMS eligibility requirements, organizations that may be exempt include:

• Smaller physician office laboratories that do not meet reporting thresholds
• Hospital laboratories that do not qualify as hospital outreach laboratories
• Laboratories that fail to meet the Medicare revenue threshold
• Organizations receiving insufficient Medicare CLFS revenue during the reporting period

Laboratories should never assume they are exempt based solely on size or ownership.

Instead, they should review CMS’s applicable laboratory guidance to determine whether reporting is required. 

What Must Laboratories Report?

Applicable laboratories must report three primary data elements for each eligible Clinical Diagnostic Laboratory Test.

HCPCS Code

Each laboratory test must be identified using the correct Healthcare Common Procedure Coding System (HCPCS) code.

Private Payer Rate

Laboratories report the final payment amount received from each private payer during the data collection period.

Associated Test Volume

The laboratory must also report how many tests were paid at each reimbursement rate.

CMS combines these three data elements to calculate future Medicare reimbursement under the Clinical Laboratory Fee Schedule. 

Accurate coding, payment data, and test volumes are all essential because errors in any of these areas can affect the final weighted median calculation used to establish Medicare payment rates.

How CMS Calculates PAMA Reimbursement Rates

One of the biggest misconceptions about PAMA is how Medicare determines reimbursement for clinical laboratory tests.

Many laboratory leaders assume CMS simply averages private payer reimbursement rates. That is not how the process works.

Instead, CMS calculates the weighted median of private payer payment rates reported by applicable laboratories. This approach gives greater influence to reimbursement rates associated with higher testing volumes rather than treating every payment equally. 

In simple terms, the payment rate received for 10,000 tests has a much larger impact than the payment rate received for 100 tests.

This methodology is designed to make Medicare reimbursement more representative of the broader private insurance market.

Step-by-Step: How CMS Calculates Reimbursement

CMS follows a structured process to establish new Clinical Laboratory Fee Schedule (CLFS) payment rates.

Step 1: Laboratories Collect Private Payer Data

Applicable laboratories gather information from final paid claims during the official data collection period.

The reported data includes:

• HCPCS code
• Final private payer payment amount
• Number of tests paid at that reimbursement rate

Only finalized payments are reported. Billed charges, expected reimbursements, or estimated payment amounts are not acceptable. 

Step 2: Data Is Submitted to CMS

During the reporting window, applicable laboratories submit their information through the CMS Clinical Laboratory Fee Schedule (CLFS) reporting system.

Reporting occurs at the Tax Identification Number (TIN) level rather than by individual laboratory locations. 

Step 3: CMS Organizes the Data

CMS groups the submitted information by HCPCS code.

Each laboratory test is analyzed independently.

For example:

• CPT 80053 (Comprehensive Metabolic Panel)
• CPT 80061 (Lipid Panel)
• CPT 85025 (Complete Blood Count)

Each code receives its own reimbursement calculation.

Step 4: CMS Calculates the Weighted Median

Instead of calculating an average payment, CMS identifies the weighted median based on both reimbursement amounts and testing volume.

Higher-volume payment rates influence the final reimbursement more than lower-volume rates. 

Step 5: CMS Publishes Updated CLFS Rates

Once calculations are complete, CMS publishes the updated Clinical Laboratory Fee Schedule.

These payment amounts become the official Medicare reimbursement rates for the next reporting cycle.

For the current reporting period, laboratories report data in 2026, and the resulting CLFS rates become effective on January 1, 2027. 

Example: Understanding the Weighted Median

The weighted median is easier to understand with a simple example.

Assume four private payers reimburse the same laboratory test at different rates.

Private Payer	Payment Rate	Annual Test Volume
Blue Cross Blue Shield	$18	8,000
UnitedHealthcare	$17	5,000
Medicare Advantage	$16	2,000
Aetna	$19	3,000

If you calculated the simple average, the reimbursement would be $17.50.

CMS does not use that figure.

Instead, it arranges the payment rates according to their associated testing volumes and identifies the weighted median.

Because Blue Cross Blue Shield accounts for the largest testing volume in this example, its payment rate has significantly greater influence on the final Medicare reimbursement than a payer responsible for only a small number of tests.

This is why laboratories must report both payment amounts and testing volumes accurately.

A small error in testing volume can influence the reimbursement calculation for that HCPCS code. 

Financial Impact on Clinical Laboratories

Although Congress delayed CLFS payment reductions for 2026, clinical laboratories continue to operate under significant financial pressure.

Over the past several years, laboratories have experienced rising expenses across nearly every area of their operations.

Common challenges include:

• Higher labor costs
• Inflation affecting laboratory supplies
• Increased equipment and maintenance expenses
• Growing administrative burden
• More complex payer policies
• Rising claim denial rates
• Expanded prior authorization requirements for certain services

At the same time, many laboratories rely heavily on Medicare reimbursement, particularly for routine, high-volume testing.

If reimbursement rates decrease in future years, laboratories may experience:

• Lower operating margins
• Reduced capital available for new equipment
• Delayed hiring
• Greater pressure to improve billing efficiency
• Increased focus on payer contract negotiations

For independent laboratories operating with narrow margins, even relatively small reimbursement reductions can significantly affect annual revenue.

This is why many organizations are treating 2026 as a financial planning year rather than simply a reporting year.

How PAMA Affects Different Types of Laboratories

Not every laboratory experiences PAMA in the same way. The financial impact depends on payer mix, testing volume, and the types of services provided.

Independent Clinical Laboratories

Independent laboratories often derive a significant portion of their revenue from Medicare Part B.

Because of this, changes to the Clinical Laboratory Fee Schedule can directly influence profitability, staffing decisions, and expansion plans.

These laboratories should closely monitor future reimbursement trends and ensure accurate private payer reporting.

Hospital Outreach Laboratories

Hospital outreach laboratories that bill Medicare Part B for non-patient laboratory services may qualify as applicable laboratories under PAMA.

These organizations should verify whether they meet CMS reporting requirements and confirm their reporting responsibilities well before the submission deadline. 

Physician Office Laboratories

Some physician office laboratories meet CMS’s applicable laboratory definition, while others do not.

Eligibility depends on factors such as Medicare revenue thresholds and the applicable laboratory criteria established by CMS.

Physician practices should evaluate their reporting obligations rather than assuming they are automatically exempt. 

Molecular and Genetic Laboratories

Advanced molecular and genetic testing often involves higher reimbursement amounts, evolving CPT and HCPCS coding, and rapidly changing payer policies.

These laboratories should monitor reimbursement updates carefully because payment changes may vary significantly by individual test.

Toxicology Laboratories

Toxicology laboratories frequently manage complex payer rules, medical necessity requirements, and documentation standards.

Future Medicare reimbursement changes, combined with commercial payer policy updates, can significantly influence overall collections.

Strong coding practices and proactive denial management are essential for maintaining revenue.

Pathology Laboratories

Pathology laboratories perform a wide range of diagnostic services, including surgical pathology, cytopathology, molecular pathology, immunohistochemistry, and flow cytometry.

Because reimbursement varies by HCPCS code and testing volume, pathology laboratories should monitor CLFS updates closely and ensure accurate reporting across all applicable services.

Common Reporting Mistakes Laboratories Should Avoid

Submitting a PAMA report is not simply an administrative task. It requires accurate billing, coding, finance, and compliance data.

Some of the most common mistakes include:

Reporting billed charges instead of final paid amounts

CMS requires laboratories to report final private payer payment amounts, not billed charges or expected reimbursement. 

Incorrect HCPCS mapping

Using outdated or incorrect HCPCS codes may result in inaccurate reimbursement calculations.

Missing payer data

Incomplete reporting can affect the quality of the submitted data and increase compliance risk.

Incorrect testing volumes

Because CMS uses a weighted median methodology, inaccurate testing volumes may influence the final Medicare reimbursement calculation.

Poor documentation

Laboratories should maintain detailed supporting documentation for reported payment data in case of future audits or validation requests.

Accurate reporting begins long before the submission deadline. It requires coordination between billing teams, finance departments, compliance officers, and laboratory leadership.

Preparing Your Laboratory for 2027

Although Medicare reimbursement rates remain unchanged throughout 2026, laboratories should not view this year as a pause. Instead, it is an opportunity to strengthen internal processes before new Clinical Laboratory Fee Schedule (CLFS) rates take effect in 2027.

The quality of the data submitted during the 2026 reporting window will influence future Medicare reimbursement. At the same time, laboratories continue to face rising operating costs, increasing payer complexity, and tighter compliance expectations.

A proactive approach now can help reduce both financial and operational risk. 

Financial Planning Strategies Before 2027

Laboratories should begin evaluating how potential reimbursement changes could affect revenue, staffing, and long-term growth. Rather than waiting for CMS to publish new payment rates, organizations can take several practical steps now.

Review Medicare Revenue by Test

Identify which CPT and HCPCS codes generate the highest Medicare revenue.

Pay particular attention to:

• High-volume routine testing
• Molecular diagnostics
• Toxicology testing
• Pathology services
• Genetic testing

Understanding your revenue mix helps prioritize areas that may experience the greatest financial impact.

Benchmark Commercial Payer Reimbursement

PAMA bases Medicare reimbursement on private payer payment rates.

Laboratories should compare reimbursement across commercial insurers to identify:

• Underperforming payer contracts
• Significant reimbursement variation
• Opportunities for contract renegotiation

Organizations that understand their commercial reimbursement patterns are better prepared for future Medicare payment changes.

Strengthen Revenue Cycle Performance

Improving revenue cycle efficiency can offset reimbursement pressure.

Focus on key performance indicators such as:

• First-pass claim acceptance rate
• Claim denial rate
• Net collection rate
• Days in accounts receivable
• Underpayment recovery rate
• Appeal success rate

Even modest improvements in these metrics can help protect revenue if Medicare reimbursement declines.

Improve Coding and Documentation

Incorrect coding remains one of the leading causes of laboratory claim denials.

Laboratories should regularly audit:

• CPT coding accuracy
• HCPCS mapping
• ICD-10-CM diagnosis coding
• Medical necessity documentation
• LCD and NCD compliance

Better documentation supports cleaner claims and reduces avoidable payment delays.

Invest in Reporting and Analytics

Modern revenue cycle analytics help laboratories identify reimbursement trends before they become financial problems.

Useful reports include:

• Revenue by payer
• Revenue by CPT code
• Denial trends
• Underpayment analysis
• Medicare reimbursement forecasts
• Payer-specific payment turnaround times

Organizations that monitor these metrics continuously can make more informed financial decisions.

Common Myths About PAMA

Despite being in effect for more than a decade, PAMA remains widely misunderstood.

Myth 1: PAMA Has Been Repealed

Reality: PAMA remains the law. Congress has delayed scheduled payment reductions several times, but the reporting requirements and market-based reimbursement methodology remain in place. 

Myth 2: No Payment Cuts in 2026 Means No Action Is Required

Reality: The absence of reimbursement reductions in 2026 does not eliminate reporting obligations.

Private payer data reported between May 1 and July 31, 2026 will determine Medicare reimbursement beginning January 1, 2027. 

Myth 3: Only Independent Laboratories Are Affected

Reality: Depending on CMS eligibility requirements, reporting may apply to independent laboratories, hospital outreach laboratories, and certain physician office laboratories. 

Myth 4: PAMA Only Impacts Medicare

Reality: Although PAMA directly affects Medicare reimbursement, many commercial insurers monitor Medicare payment trends when evaluating their own reimbursement policies.

Changes to CLFS rates can therefore influence broader laboratory revenue over time.

2026 PAMA Compliance Checklist

Before the July 31, 2026 reporting deadline, laboratories should confirm that every reporting requirement has been completed.

Reporting Preparation Checklist

• Confirm your organization qualifies as an applicable laboratory.
• Verify reporting responsibilities at the Tax Identification Number (TIN) level.
• Review HCPCS code mapping.
• Validate private payer payment amounts.
• Confirm testing volumes.
• Reconcile billing and finance reports.
• Review corrected claims and payment adjustments.
• Ensure only final paid claims are reported.
• Complete Submitter and Certifier registration if required.
• Maintain supporting documentation for future audits.
• Submit all required data before July 31, 2026. 

Final Thoughts

The 2026 PAMA updates provide temporary relief from Medicare reimbursement cuts, but they also mark one of the most important reporting periods since the law was enacted.

For laboratory leaders, the priority this year is not responding to lower reimbursement rates. It is ensuring that private payer data is complete, accurate, and submitted on time. The information reported during the 2026 reporting window will directly influence Medicare reimbursement beginning in 2027 and could shape laboratory revenue for years to come. 

Organizations that take a proactive approach by validating payer data, strengthening coding accuracy, improving revenue cycle performance, and monitoring CMS guidance will be better positioned to adapt to future reimbursement changes while maintaining financial stability.

 

References

• Centers for Medicare & Medicaid Services (CMS). Clinical Laboratory Fee Schedule (CLFS) & PAMA Reporting Resources.
• National Independent Laboratory Association (NILA). PAMA Resources. 
• American Medical Association (AMA). National Advocacy Update: PAMA Mandatory Lab Reporting. 
• XiFin. PAMA and the RESULTS Act. 

 

Frequently Asked Questions

1- What are the PAMA reimbursement rates for 2026?

There are no new CLFS payment reductions in 2026. Medicare continues using the existing Clinical Laboratory Fee Schedule throughout the year. 

2- When is the PAMA reporting deadline in 2026?

Applicable laboratories must report private payer data between May 1 and July 31, 2026. 

3- What data must laboratories report under PAMA?

Reporting includes:

• HCPCS codes
• Final private payer payment amounts
• Associated testing volumes

CMS uses this information to calculate future Medicare reimbursement rates. 

4- When will the next Medicare reimbursement rates become effective?

The reimbursement rates based on the current reporting cycle become effective on January 1, 2027. 

5- How much can Medicare reimbursement decrease after 2026?

Current law limits payment reductions to 15% per year for 2027 through 2029 compared with the preceding year’s payment amount. 

6- Does every laboratory need to submit PAMA data?

No. Only laboratories that meet CMS’s definition of an applicable laboratory are required to report private payer information.